广州医科大学×中山大学合作Cell子刊：发现增强铁死亡抗癌效果的新靶点

Core Viewpoint - Ferroptosis is a newly discovered iron-dependent form of programmed cell death that plays a significant role in the development of various diseases, including cancer, and represents a promising new strategy for cancer treatment by inducing lipid peroxidation [1][6]. Group 1: Research Findings - The study published in Molecular Cell highlights that PRDX6 is a key regulatory factor of GPX4, which helps resist ferroptosis, and targeting PRDX6 can enhance the anti-tumor effects mediated by ferroptosis [2][6]. - The research team identified that PRDX6 influences the localization and function of GPX4, thereby contributing to the resistance against ferroptosis [3][6]. - PRDX6 has phospholipase A2 activity, catalyzing the conversion of peroxidized phospholipids into lysolipids and oxidized fatty acids, which is crucial for its interaction with GPX4 [4][6]. Group 2: Implications for Cancer Treatment - Combining PRDX6 inhibition with ferroptosis inducers can increase lipid peroxidation and effectively suppress tumor growth in mouse models of liver and ovarian cancer, including patient-derived models [4][6]. - High expression of PRDX6 is associated with shorter progression-free survival in various human cancer types, indicating its potential as a therapeutic target [4][6].